surmount-1 tirzepatide weight loss non-diabetic 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with obesity or overweight but without diabetes. Researchers SURMOUNT‐1 study design. This is

Laboratory research record on GLP-1S [PMID: 39757501] PubMed laboratory record discussing GLP-1S in a research context

Appetite drops further

Through interdisciplinary centres, labs, and collaborative partnerships, UNAM aims to produce high-impact outputs addressing local, national, continental, and global challenges

Nevertheless, the medication is contraindicated in patients with a personal or family history of this condition or Multiple Endocrine Neoplasia syndrome type 2

Honey, an ancient natural product used in ethnomedicine, has been the focus of recent attention due to its multifactorial biochemical composition and possible anticancer properties

Book an appointment today for our Semaglutide treatment